Vizora日本語

Kidswell BioKidswell Bio Corporation4584東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP

Kidswell Bio FY ending Mar 2021 results

Kidswell Bio brought in ¥996.5M in revenue.

It lost about ¥97 for every ¥100 of sales at the operating level.

Revenue changed -7.5% from the prior year.

What changed from last year

FY ending Mar 2020 → FY ending Mar 2021

Revenue
-7.5%¥1.08B → ¥996.5M
Gross profit
+106.6%¥424.6M → ¥877M
Operating income
Loss-¥1.16B → -¥969.7M
Net income attributable to owners
Loss-¥7.32B → -¥1B
Operating cash flow
Loss-¥1.33B → -¥1.27B

Where the money goes

FY ending Mar 2020 → FY ending Mar 2021

Where ¥100 of sales goes

For every ¥100 Kidswell Bio sells, how much goes where, and how much is kept.

FY ending Mar 2021
Cost of sales
¥12
SG&A
¥185
Operating loss
¥97
Net loss
¥100

Annual margin trends

Gross margin88.0%
FY ending Mar 2020: 39.4%39.4%FY ending Mar 2021: 88.0%88.0%FY20FY21
Operating margin-97.3%
FY ending Mar 2020: -107.8%-107.8%FY ending Mar 2021: -97.3%-97.3%FY20FY21
Net margin-100.5%
FY ending Mar 2020: -678.9%-678.9%FY ending Mar 2021: -100.5%-100.5%FY20FY21

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第25期(2024/04/01－2025/03/31)

    ID S100W8G22025-06-27Open

  • EDINET (FSA Japan)

    有価証券報告書－第22期(令和3年4月1日－令和4年3月31日)

    ID S100OITB2022-06-28Open

  • EDINET (FSA Japan)

    有価証券報告書－第21期(令和2年4月1日－令和3年3月31日)

    ID S100LVK52021-06-30Open

Extracted from XBRL: 41

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image